EZH1 and Miyoshi myopathy: Ola Rizq et al. reported that patients with MM who have higher levels of EZH2 expression tend to respond poorly to bortezomib, thus, inhibition of both EZH1 and EZH2 sensitizes MM to PI treatment at a synergetic manner, mainly through suppression of PRC-2–dependent H3K27me3 (31).